IRIS to Host Financial Analyst Briefing At American Association for Clinical Chemistry (AACC) 2009 Annual Meeting and Clinical Lab Expo in Chicago On July 22nd

CHATSWORTH, Calif., June 29, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that IRIS senior management, led by Cesar Garcia, Chairman and CEO, will host a financial analyst breakfast briefing and presentation on Wednesday, July 22, 2009, in conjunction with the American Association for Clinical Chemistry (AACC) 2009 Annual Meeting and Clinical Lab Exposition in Chicago, IL.

The analyst event will begin at 7:30 a.m. Central time at the Hyatt Regency McCormick Place Hotel, 2233 South Martin Luther King Drive, Chicago, IL. Immediately following the presentation, IRIS will conduct a tour and product demonstration at its booth on the floor of the AACC Clinical Lab Expo at the McCormick Place Convention Center.

Attendance is by invitation only and limited to financial analysts and institutional investors. Those interested in attending are asked to contact Ron Stabiner at The Wall Street Group, Inc., 212-888-4848, or rstabiner@thewallstreetgroup.com.

About IRIS International, Inc.

IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,230 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(r), platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.

CONTACT:  IRIS International, Inc.
          Cesar Garcia, Chairman and Chief Executive Officer
          818-709-1244, x 7123

          The Wall Street Group, Inc.
          Ron Stabiner
          212-888-4848